Moleculin Biotech, Inc. — Form 10-Q Summary
Reporting period: Three and nine months ended September 30, 2022. Moleculin is a clinical-stage pharmaceutical company developing drug candidates for resistant cancers and viruses; it reported no revenue. Amounts below are in U.S. dollars unless stated otherwise.
Financial results and liquidity
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development expense | $5.965 million | $4.095 million | $14.790 million | $11.239 million |
| General and administrative expense | $3.087 million | $2.021 million | $8.704 million | $6.394 million |
| Total operating expenses | $9.084 million | $6.157 million | $23.592 million | $17.763 million |
| Net loss | $8.611 million | $4.379 million | $22.255 million | $13.069 million |
| Basic and diluted loss per share | $0.30 | $0.15 | $0.78 | $0.50 |
| Cash used in operating activities | — | $20.383 million | $14.693 million |
- At September 30, cash and cash equivalents were $50.392 million, down from $70.903 million at December 31, 2021. Current assets were $53.493 million and current liabilities were $6.362 million, for working capital of approximately $47.1 million.
- Total liabilities were $6.955 million, including a $0.228 million warrant liability and lease liabilities. The filing reports no conventional borrowings or debt balance.
- Management said existing cash was expected to fund projected operations beyond the second quarter of 2024, including a potential increase in R&D spending. This estimate depends on clinical and preclinical activity and other costs; additional financing may be needed.
- Operating margins are not meaningful because the company had no revenue. The $1.184 million nine-month gain from revaluing warrant liabilities reduced reported loss; this is a fair-value accounting item, not operating revenue.
Changes versus the comparable period
- Q3 net loss increased by $4.232 million year over year; nine-month net loss increased by $9.186 million.
- Nine-month R&D expense rose $3.551 million, primarily from increased clinical-trial activity, additional drug-product manufacturing, and a license termination fee. Nine-month G&A expense rose $2.310 million, mainly due to regulatory and legal services and consulting and advisory fees.
- Nine-month operating cash use increased $5.690 million. The company reported no stock-sale proceeds in the 2022 period, compared with $74.685 million net proceeds from stock sales in the first nine months of 2021.
- Cash declined by $20.511 million during the first nine months of 2022. Shares outstanding were 28,627,827 at September 30, 2022, compared with 28,578,338 at year-end 2021.
Business developments, outlook and risks
- The company described six drug candidates across Annamycin, WP1066 and WP1122 portfolios; three candidates had shown human activity in clinical trials. Its strategy is to seek outlicensing or other strategic partners for development and commercialization.
- Annamycin’s U.S. Phase 1b study for soft-tissue sarcoma lung metastases advanced to Phase 2. The first three Phase 2 subjects received 360 mg/m²; adverse events, primarily myelosuppression, prompted a reduction in the recommended Phase 2 dose to 330 mg/m². Preliminary outcomes for these subjects were mixed and incomplete, including disease progression in two reported cases. The company planned to treat at least 25 subjects in Phase 2.
- Enrollment opened in a Polish Phase 1/2 Annamycin-plus-cytarabine study for relapsed or refractory acute myeloid leukemia. Separately, an externally funded Polish Annamycin trial for sarcoma lung metastases began dosing subjects.
- The filing reported an independent cardiology review finding no preliminary signal of excessive cardiotoxicity in the assessed Annamycin subjects. The company emphasized that ongoing safety and efficacy data collection is necessary; these observations do not establish safety or effectiveness.
- WP1066’s Emory pediatric brain-tumor trial enrolled its final subject in October 2022. The company discussed possible future externally funded studies and continued work on intravenous formulations.
- WP1122’s Phase 1a healthy-volunteer study was concluded after the company determined a daily cumulative dose of 32 mg/kg was the maximum tolerated dose. Management said further development would proceed only if external funding is available. The filing also noted FDA orphan-drug designation for WP1122 in glioblastoma.
- In March 2022, the company received an SEC subpoena seeking information, including materials related to individuals and entities and statements about its COVID-19 drug candidate. The company said it did not know the investigation’s specific nature and could not predict its outcome. It incurred approximately $1.9 million in related legal fees through September and estimated a further approximately $1.0 million for Q4 2022.
- Other risks include clinical-trial recruitment, regulatory approvals and delays, candidate efficacy, reliance on third-party manufacturers, supply-chain and geopolitical disruptions, intellectual-property obligations, and the availability and terms of future financing. Management anticipates operating losses for several years and no near-term positive operating cash flow.
- The company disclosed a $400,000 license termination expense in the first nine months of 2022. It also granted 250,000 ten-year warrants at $1.24 per share to a related-party advisory entity in September 2022.
Important facts for investors to verify
- Cash runway assumptions and whether clinical-trial spending, legal costs, or other commitments change the projected funding horizon.
- Enrollment, dose tolerability, safety signals, and efficacy results in Annamycin trials, especially the Phase 2 sarcoma study and the AML combination study.
- The progress and external funding status of WP1066 and WP1122 programs, including any planned studies or partnerships.
- Updates on the SEC investigation, related legal expenses, and any resulting actions or disclosure changes.
- Future financing needs, potential share dilution, and the impact of outstanding warrants and equity compensation.